-
公开(公告)号:US5192768A
公开(公告)日:1993-03-09
申请号:US757988
申请日:1991-09-12
申请人: Fumio Suzuki , Yoshisuke Nakasato , Kenji Ohmori , Tadafumi Tamura , Hisashi Hosoe , Kazuhiro Kubo , Ikufumi Yoshitake
发明人: Fumio Suzuki , Yoshisuke Nakasato , Kenji Ohmori , Tadafumi Tamura , Hisashi Hosoe , Kazuhiro Kubo , Ikufumi Yoshitake
IPC分类号: C07D471/04
CPC分类号: C07D471/04
摘要: A pyrazoloquinoline derivative having the formula (I): ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 independently represent a hydrogen atom or a lower alkyl group; R.sup.4 represents a hydrogen atom, a lower alkyl group, a halogen-substituted lower alkyl group, or a lower alkoxycarbonyl group; the dotted line means that the pyrazole ring has two conjugated double bonds; and R.sup.4 is bonded to the nitrogen atom at the 1-position or 2-position, or pharmacologically acceptable salts thereof. These compounds exhibit excellent anti-inflammatory activity and hepatic insufficiency treating activity.
-
公开(公告)号:US5270316A
公开(公告)日:1993-12-14
申请号:US599758
申请日:1990-10-19
申请人: Fumio Suzuki , Junichi Shimada , Takeshi Kuroda , Kazuhiro Kubo , Akira Karasawa , Tetsuji Ohno , Kenji Ohmori
发明人: Fumio Suzuki , Junichi Shimada , Takeshi Kuroda , Kazuhiro Kubo , Akira Karasawa , Tetsuji Ohno , Kenji Ohmori
IPC分类号: A61K31/00 , A61K31/495 , A61K31/505 , A61K31/519 , A61K31/529 , A61P7/00 , A61P7/10 , A61P9/00 , A61P9/12 , A61P11/00 , A61P11/06 , A61P11/08 , A61P13/00 , A61P13/02 , A61P13/12 , A61P15/00 , C07D471/14 , C07D487/14 , A61K31/52
CPC分类号: C07D471/14 , C07D487/14
摘要: There are disclosed condensed purine derivatives represented by formula; ##STR1## in which R.sup.3 represents hydrogen, lower alkyl or benzyl; each of X.sup.1 and X.sup.2 independently represents hydrogen, lower alkyl, aralkyl or phenyl; and n is an integer of 0 or 1; R.sup.1 represents hydrogen, lower alkyl, alicyclic alkyl, noradamantan-3-yl, dicyclopropylmethyl or styryl; and R.sup.2 represents hydrogen, lower alkyl or alicyclic alkyl; or a pharmaceutically acceptable salt thereof. The derivatives and pharmaceutically acceptable salts are useful as diuretics, renal protecting agents, antiallergic agents and hypotensives.
-
公开(公告)号:US5525607A
公开(公告)日:1996-06-11
申请号:US63684
申请日:1993-05-20
申请人: Fumio Suzuki , Junichi Shimada , Akio Ishii , Tetsuji Ohno , Akira Karasawa , Kazuhiro Kubo , Hiromi Nonaka , Fumio Suzuki , Junichi Shimada , Akio Ishii , Tetsuji Ohno , Akira Karasawa , Kazuhiro Kubo , Hiromi Nonaka
发明人: Fumio Suzuki , Junichi Shimada , Akio Ishii , Tetsuji Ohno , Akira Karasawa , Kazuhiro Kubo , Hiromi Nonaka , Fumio Suzuki , Junichi Shimada , Akio Ishii , Tetsuji Ohno , Akira Karasawa , Kazuhiro Kubo , Hiromi Nonaka
IPC分类号: C07D473/06 , C07D473/08 , C07D473/20 , C07D473/22 , A61K31/52 , C07D473/00
CPC分类号: C07D473/06 , C07D473/08 , C07D473/20 , C07D473/22
摘要: Novel xanthine compounds represented by the following formula: ##STR1## wherein each of R.sup.1, R.sup.2 and R.sup.3 independently represents hydrogen or lower alkyl;each of X.sup.1 and X.sup.2 independently represents oxygen or sulfur; and Q represents: ##STR2## The compounds are useful as a diuretic, a renal-protecting agent and bronchodilator.
摘要翻译: 由下式表示的新型黄嘌呤化合物:其中R 1,R 2和R 3各自独立地表示氢或低级烷基; X1和X2各自独立地表示氧或硫; Q表示:该化合物可用作利尿剂,肾保护剂和支气管扩张剂。
-
公开(公告)号:US5302602A
公开(公告)日:1994-04-12
申请号:US884208
申请日:1992-05-18
申请人: Etsuo Oshima , Hiroyuki Obase , Akira Karasawa , Kazuhiro Kubo , Ichiro Miki , Akio Ishii , Hidee Ishii , Kenji Ohmori
发明人: Etsuo Oshima , Hiroyuki Obase , Akira Karasawa , Kazuhiro Kubo , Ichiro Miki , Akio Ishii , Hidee Ishii , Kenji Ohmori
IPC分类号: C07D211/14 , C07D313/12 , C07D333/34 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D471/10 , A61K31/445 , C07D211/22
CPC分类号: C07D405/06 , C07D211/14 , C07D313/12 , C07D333/34 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D471/10
摘要: Novel tricyclic compounds having a TXA.sub.2 antagonizing activity represented by formula (I): ##STR1## possess a potent antagonizing against thromboxane A.sub.2 and also an antiallergic and/or antihistaminic activity, and are expected to have preventive and therapeutic effects on ischemic diseases, cerebro-vascular diseases, etc.
摘要翻译: 具有由式(I)表示的TXA2拮抗活性的新型三环化合物:具有对血栓素A2的有效拮抗作用,还具有抗过敏和/或抗组胺活性,并且预期对缺血性疾病具有预防和治疗作用 脑血管疾病等
-
公开(公告)号:US5143922A
公开(公告)日:1992-09-01
申请号:US616095
申请日:1990-11-20
申请人: Etsuo Oshima , Hiroyuki Obase , Akira Karasawa , Kazuhiro Kubo , Ichiro Miki , Akio Ishii , Hidee Ishii , Kenji Ohmori
发明人: Etsuo Oshima , Hiroyuki Obase , Akira Karasawa , Kazuhiro Kubo , Ichiro Miki , Akio Ishii , Hidee Ishii , Kenji Ohmori
IPC分类号: C07D211/14 , C07D313/12 , C07D333/34 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D471/10
CPC分类号: C07D405/06 , C07D211/14 , C07D313/12 , C07D333/34 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D471/10
摘要: Novel tricyclic compounds having a TXA.sub.2 antagonizing activity represented by formula (I): ##STR1## possess a potent antagonizing action against thromboxane A.sub.2 and also an antiallergic and/or antihistaminic acitvity, and are expected to have preventive and therapeutic effects on ischemic diseases, cerebro-vascular diseases, etc.
摘要翻译: 具有由式(I)表示的TXA2拮抗活性的新型三环化合物:对抗凝血恶烷A2具有有效的拮抗作用,并且还具有抗过敏和/或抗组胺活性,并且预期对缺血性具有预防和治疗作用 疾病,脑血管疾病等
-
公开(公告)号:US4994463A
公开(公告)日:1991-02-19
申请号:US281545
申请日:1988-12-08
申请人: Etsuo Oshima , Hiroyuki Obase , Akira Karasawa , Kazuhiro Kubo , Ichiro Miki , Akio Ishii , Hidee Ishii , Kenji Ohmori
发明人: Etsuo Oshima , Hiroyuki Obase , Akira Karasawa , Kazuhiro Kubo , Ichiro Miki , Akio Ishii , Hidee Ishii , Kenji Ohmori
IPC分类号: C07D211/14 , C07D313/12 , C07D333/34 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D471/10
CPC分类号: C07D405/06 , C07D211/14 , C07D313/12 , C07D333/34 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D471/10
摘要: Novel tricyclic compounds having a TXA.sub.2 antagonizing activity represented by formula (I): ##STR1## possess a potent antagonizing action against thromboxane A.sub.2 and also an antiallergic and/or antihistaminic activity, and are expected to have preventive and therapeutic effects on ischemic diseases, cerebro-vascular diseases, etc.
-
公开(公告)号:US5068236A
公开(公告)日:1991-11-26
申请号:US486831
申请日:1990-03-01
申请人: Fumio Suzuki , Junichi Shimada , Kazuhiro Kubo , Tetsuji Ohno , Akira Karasawa , Akio Ishii , Hiromi Nonaka
发明人: Fumio Suzuki , Junichi Shimada , Kazuhiro Kubo , Tetsuji Ohno , Akira Karasawa , Akio Ishii , Hiromi Nonaka
IPC分类号: A61K31/52 , A61K31/522 , A61P7/10 , A61P9/08 , A61P9/12 , A61P13/02 , A61P15/00 , C07D473/04 , C07D473/06 , C07D473/08 , C07D473/10 , C07D473/12 , C07D473/20 , C07D473/22
CPC分类号: C07D473/04 , C07D473/06 , C07D473/22
摘要: Novel xanthine compounds represented by the following formula: ##STR1## and pharmaceutically acceptable salts thereof have a diuretic action, a renal-protecting action and a vasodilative action.The compounds are useful as a diuretic, a renal-protecting agent and an antihypertensive agent.
-
公开(公告)号:US5290782A
公开(公告)日:1994-03-01
申请号:US839690
申请日:1992-02-24
申请人: Fumio Suzuki , Junichi Shimada , Akio Ishii , Tetsuji Ohno , Akira Karasawa , Kazuhiro Kubo , Hiromi Nonaka
发明人: Fumio Suzuki , Junichi Shimada , Akio Ishii , Tetsuji Ohno , Akira Karasawa , Kazuhiro Kubo , Hiromi Nonaka
IPC分类号: C07D473/06 , C07D473/08 , C07D473/20 , C07D473/22 , C07D473/02 , A61K31/52
CPC分类号: C07D473/06 , C07D473/08 , C07D473/20 , C07D473/22
摘要: Novel xanthine compounds represented by the following formula: ##STR1## wherein each of X.sup.1 and X.sup.2 independently represents oxygen or sulfur; and Q represents; ##STR2## where ----- represents a single bond or a double bond; Y represents a single bond or alkylene, n represents 0 or 1, each of W.sup.1 and W.sup.2 independently represents hydrogen, lower alkyl or amino, Z represents --CH.sub.2 -, --O--, --S-- or --NH--; represents ##STR3## each of R.sup.1 and R.sup.2 independently represents hydrogen, lower alkyl, allyl or propargyl; and R.sup.3 represents hydrogen or lower alkyl, and when Q represents the groups other than ##STR4## each of R.sup.1, R.sup.2 and R.sup.3 independently represents hydrogen or lower alkyl;provided that when Q is ##STR5## then R.sup.1 R.sup.2 and R.sup.3 are notsimultaneously methyl; and pharmaceutically acceptable salts thereof have a diuretic effect, a renal-protecting effect and a bronchodilatory effect.
摘要翻译: 由下式表示的新型黄嘌呤化合物:其中X1和X2各自独立地表示氧或硫; 和Q表示;
其中-----表示单键或双键; Y表示单键或亚烷基,n表示0或1,W1和W2各自独立地表示氢,低级烷基或氨基,Z表示-CH2 - , - O - , - S-或-NH-。 R1和R2各自表示氢,低级烷基,烯丙基或炔丙基; 且R 3表示氢或低级烷基,并且当Q表示除R1之外的基团时,R 1,R 2和R 3各自独立地表示氢或低级烷基; 条件是当Q为 时,则R1 + L,R2和R3不同时为甲基; 及其药学上可接受的盐具有利尿作用,肾脏保护作用和支气管扩张作用。 -
公开(公告)号:US5120737A
公开(公告)日:1992-06-09
申请号:US764827
申请日:1991-09-24
申请人: Fumio Suzuki , Hiroaki Hayashi , Kazuhiro Kubo , Junichi Ikeda
发明人: Fumio Suzuki , Hiroaki Hayashi , Kazuhiro Kubo , Junichi Ikeda
IPC分类号: C07D493/04
CPC分类号: C07D493/04
摘要: A hexitol derivative represented by formula (I) ##STR1## wherein R represents hydrogen, unsubstituted or lower alkyl-substituted cycloalkyl, lower alkenyl, lower alkoxy, lower alkanoyl, piperidyl or ##STR2## wherein each of m and n independently represents an integer of 0 to 3; each of X, Y and Z independently represents hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, lower alkanoyloxy, hydroxyl, halogen or nitro or a pharmaceutically acceptable salt thereof.
-
公开(公告)号:US5053408A
公开(公告)日:1991-10-01
申请号:US508701
申请日:1990-04-13
申请人: Fumio Suzuki , Hiroaki Hayashi , Takeshi Kuroda , Kazuhiro Kubo , Junichi Ikeda
发明人: Fumio Suzuki , Hiroaki Hayashi , Takeshi Kuroda , Kazuhiro Kubo , Junichi Ikeda
IPC分类号: A61K31/00 , A61K31/495 , A61K31/496 , A61K31/505 , A61P9/00 , A61P9/08 , A61P9/10 , C07D493/04 , C07D519/00
CPC分类号: C07D493/04
摘要: Disclosed is a hexitol derivative represented by the formula (I): ##STR1## wherein Q represents a formula selected from the group consisting of ##STR2## wherein a represents NH, O or S;each of b, c and d independently represents CH or N;each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represents hydrogen, lower alkyl, trifluoromethyl, aryl, lower alkanoyloxy, amino, lower alkylamino, lower alkanoylamino, lower alkanoyl, aroyl, halogen, nitro, (CH.sub.2).sub.m OR.sup. 7, (CH.sub.2).sub.m SR.sup.7, (CH.sub.2).sub.m CO.sub.2 R.sup.7 where R.sup.7 represents hydrogen or lower alkyl and m represents an integer of 0 to 3;each of R.sup.5 and R.sup.6 independently represents hydrogen or lower alkyl;U represents >N-- or ##STR3## W represents a single bond, --O-- or --S--; X represents ##STR4## wherein each of Y.sup.1 and Y.sup.2 independently represents hydrogen, lower alkyl, hydroxyl, lower alkanoyloxy, nitrile or phenyl; or Y.sup.1 and Y.sup.2 are combined together to form oxygen;each of Y.sup.3 and Y.sup.4 independently represents hydrogen or lower alkyl; and l is an integer of 0 to 6, and where l is an integer of 2 to 6, each ##STR5## may be the same or different; Z represents hydrogen or nitro; and, n is 2 or 3 or a pharmaceutically acceptable salt thereof. The compounds show prominent coronary vasodilative activities, and are useful in treating angina pectoris and myocardial infarction.
-
-
-
-
-
-
-
-
-